InSync ICD Joins Contak For Dual Indication: 100,000 CRT Patients Eligible
This article was originally published in The Gray Sheet
Executive Summary
Medtronic expects FDA approval of the InSync ICD on June 26 will allow the company to control 60% of the 750,000-patient U.S. cardiac resynchronization therapy (CRT) market
You may also be interested in...
JAMA Editorial Praises MIRACLE ICD Study, Calls For More Substudies
An editorial by a Johns Hopkins physician in the May 28 Journal of the American Medical Association lends support to a growing number of electrophysiologists who have called on manufacturers to develop improved leads and guiding systems for cardiac resynchronization technology
JAMA Editorial Praises MIRACLE ICD Study, Calls For More Substudies
An editorial by a Johns Hopkins physician in the May 28 Journal of the American Medical Association lends support to a growing number of electrophysiologists who have called on manufacturers to develop improved leads and guiding systems for cardiac resynchronization technology
Guidant Stresses Rapid Contak Physician Training To Make Up For Lost Time
Guidant has set a goal of training at least 800 physicians on use of its Contak CD by the end of June. The implantable cardioverter defibrillator was approved May 2 for resynchronization therapy to treat heart failure